1 / 11

Palivizumab : a centralised clinic

Palivizumab : a centralised clinic. Laura Marshall RCN Conference 13 th March 2008. Pavilizumab. Initially marketed in the late 1990’s to prevent the incidence of RSV+ in under two’s. Due to lack of evidence and cost the JCVI made a tightened ‘at risk’ criteria for prescribing.

sasson
Download Presentation

Palivizumab : a centralised clinic

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Palivizumab: a centralised clinic Laura Marshall RCN Conference 13th March 2008

  2. Pavilizumab • Initially marketed in the late 1990’s to prevent the incidence of RSV+ in under two’s. • Due to lack of evidence and cost the JCVI made a tightened ‘at risk’ criteria for prescribing. • Therefore by utilising these guideline a local protocol was implemented.

  3. Local criteria • Children under one year of age with chronic lung disease, receiving home oxygen therapy or prolonged oxygen use to a corrected gestational age of 36 weeks. • Infants less than six months of age with a haemodynamically significant left to right shunt.  Infants were selected at the discretion of the paediatric cardiologist • Children under two years of age with severe congenital immuno-deficiency. • Each child receives 5 doses (Oct-Feb) 15mg/kg of pavilizumab

  4. Historical Background • Prior to the centralised clinic babies were receiving individual home visits by a CCN per dose or attending an outpatient facility • Implications: • Time • Cost • Inability to vial share • In order to refine service delivery decided to pilot a centralised CCN led clinic

  5. Working Party • Working party set up in March 2006: • Lead CCN • Paediatric Pharmacist • Named Neonatologist • Named Paediatrician • Overall aim to not only to minimise waste and cost but to increase amount of treated children

  6. The clinic • One clinic a month (initially for 10 children) • Central location with parking • Allocated appointments • 90 minute clinic ran by two nurses • Vial sharing • Integrated care pathway • Patient held records

  7. Cost Analysis • 75 Nursing hours saved

  8. Evaluation • 100% attendance throughout season • Parent satisfaction questionnaire • Variance tracking • No children were admitted to hospital • Effective social support for families

  9. Season 2007/08 • 50 % increase in children • 100 % attendance • Suffolk PCT bought into the clinic for one patient.

  10. Conclusion • Nurse led services rapidly re shaping nursing services • Local CCNT provision varies • Communication between primary and secondary care paramount

  11. Questions? laura.marshall@chpct.nhs.uk jackie.acornely@cambridgeshirepct.nhs.uk

More Related